Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies

This study has been terminated.
(Study did not meet pre-specified objectives.)
Sponsor:
Information provided by (Responsible Party):
AVEO Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00381654
First received: September 27, 2006
Last updated: September 30, 2011
Last verified: September 2011

September 27, 2006
September 30, 2011
October 2006
December 2009   (final data collection date for primary outcome measure)
To evaluate the safety, tolerability, and dose-limiting toxicities (DLT), and determine the maximum tolerated dose (MTD) of AV-412 when administered once daily by the oral route for 4 weeks (4 weeks equals one dosing cycle) [ Time Frame: one year ] [ Designated as safety issue: Yes ]
  • MTD
  • Adverse Events
Complete list of historical versions of study NCT00381654 on ClinicalTrials.gov Archive Site
  • To characterize the pharmacokinetic (PK) profile of AV-412 in all patients. Extensive PK collection and assay to be performed in expanded MTD Cohorts [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]
  • Evaluate potential pharmacodynamic (PD) markers of AV-412 action, in expanded MTD Cohorts ONLY [ Time Frame: two years ] [ Designated as safety issue: No ]
  • Preliminary evaluation of the antineoplastic activity of AV-412 (assessed by evidence and duration of disease stabilization or objective response, and time to disease progression) [ Time Frame: two years ] [ Designated as safety issue: No ]
  • PK- PK Profile
  • PD- PD Analysis
  • State of Disease
Not Provided
Not Provided
 
Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies
A Phase 1, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Daily Oral Administration of AV-412 in Patients With Refractory or Relapsed Solid Tumor Malignancies

AV-412 is a new oral therapy developed to inhibit the growth of solid tumors in patients who have not responded to standard therapy or surgical interventions, or who have experienced relapse. This study will test the safety of AV-412 and determine the maximum tolerated dose for the treatment of solid tumors.

Although progress has been made, patients with malignancies often either progress after the traditional approach of chemotherapy, surgery, or radiotherapy, or are not candidates for these approaches because of the advances stage of disease. Novel therapies that may offer greater potential than those currently available are urgently needed.

AV 412 is a potent inhibitor of human epidermal growth factor family receptor tyrosine kinases (TKIs) and represents a growing class of anti-cancer agents. The recent introduction of TKIs has opened the door to new approaches to cancer treatment in which the goals of therapy are to halt disease progression, ameliorate symptoms, and improve patient quality of life. AV412 may inhibit growth of solid tumors, with fewer and less debilitating side effects.

This study is designed to determine the safety, tolerability and maximum tolerated dose of daily oral administration of AV 412. Patients will be assigned to escalating drug dose cohorts to determine the optimal dose. Evaluations to determine tolerability include PK, PD, and the adverse events which occur during the course of study drug administration.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Tumor
Drug: AV-412
Solid oral dosage; 4 dosage strengths; 25, 50, 100, or 200 mg per capsule Dosing Frequency: Once daily dosing for 4 weeks (4 weeks equals 1 cycle)
Experimental: A
Daily oral administration of AV-412
Intervention: Drug: AV-412
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
27
February 2010
December 2009   (final data collection date for primary outcome measure)

Criteria for Inclusion:

  1. ≥ 18 year old males or females
  2. Documented measurable or evaluable solid tumor malignancy that is relapsed, refractory, locally advanced, or metastatic
  3. Patients entered to MTD Cohort B must have:

    • Histologically or cytologically confirmed NSCLC
    • No prior therapy with erlotinib, gefitinib, or any other EGFR-kinase inhibitor
    • Previously documented exon 19 deletion and/or exon 21 L858R mutations
    • Measurable disease according to RECIST
  4. Disease that is currently refractory to, or not amenable to, standard therapy
  5. Disease that is currently not amenable to surgical intervention, due to either medical contraindications or nonresectability of the tumor
  6. Karnofsky performance status ≥ 70%, life expectancy ≥ 3 months
  7. No childbearing potential or use of effective contraception by all fertile male and female patients, during the study and for 3 months after the last dose of study drug
  8. Ability to give written informed consent

Criteria for Exclusion:

  1. Pregnant or lactating women
  2. Primary CNS malignancies; active CNS metastases
  3. Hematologic malignancies (includes: leukemia, any form; lymphoma; and multiple myeloma)
  4. Active second malignancy or history of another malignancy within 2 years with the exception of:

    • Treated, non-melanoma skin cancers
    • Treated CIS of the breast or cervix
    • Controlled, superficial bladder carcinoma
    • T1a or b prostate carcinoma involving < 5% of resected tissue and PSA within normal limits (WNL)
  5. Any of the following hematologic abnormalities:

    • Hemoglobin ≤ 9.0 g/dL
    • ANC < 1,500 per mm3
    • Platelet count < 100,000 per mm3
  6. Any of the following serum chemistry abnormalities:

    • Total bilirubin > 1.5 × the ULN
    • AST or ALT ≥ 3 × the ULN (≥ 5 × if due to hepatic involvement by tumor)
    • Serum albumin < 2.5 g/dL
    • Creatinine ≥ 1.5 × ULN (or calculated CLCR < 50 mL/min/1.73 m2)
  7. Significant cardiovascular disease, including:

    • CHF requiring therapy
    • Ventricular arrhythmia requiring therapy
    • Any conduction disturbance (including patients with QTc interval prolongation > 0.47 sec, history of a severe arrhythmia, or history of a familial arrhythmia [eg, WPW])
    • Angina pectoris requiring therapy
    • LVEF < 50% by MUGA or Echocardiogram
    • Uncontrolled HTN
    • MI within 6 months of study entry
    • NYHA > Class I
  8. Significant gastrointestinal abnormalities, including:

    • Requirement for IV alimentation
    • Prior surgical procedures affecting absorption
    • Active peptic ulcer disease
    • ≥Grade 2 diarrhea due to any etiology
  9. Known history of significant ophthalmologic abnormalities, including:

    • Severe dry-eye syndrome
    • Keratoconjunctivitis sicca
    • Sjogren's syndrome
    • Severe exposure keratopathy
    • Disorders increasing risk for epithelium-related complications
  10. Serious/active infection; infection requiring parenteral antibiotics
  11. Inadequate recovery from prior antineoplastic therapy
  12. Inadequate recovery from any prior surgical procedure; major surgical procedure within 2 weeks
  13. Life-threatening illness or organ system dysfunction compromising safety evaluation
  14. Psychiatric disorder, altered mental status precluding informed consent or necessary testing
  15. Inability to comply with protocol requirements
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Argentina,   United States
 
NCT00381654
AV-412-06-101
No
AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc.
Not Provided
Principal Investigator: Manuel Hidalgo, MD, PhD Johns Hopkins University
Principal Investigator: Justina L Martinez, MD Hospital Universitatrio Austral
Principal Investigator: Carmen S. Puparelli, MD Instituto Médico Especializado Alexander Fleming
Principal Investigator: Belén R. Viquiera, M.D. Centro Integral Oncológica Clara Campal
AVEO Pharmaceuticals, Inc.
September 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP